Evidence Hub

Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome

Engelberg LA, Lerner CW, Tapper ML

The American review of respiratory disease, 1984

19 participants

Abstract

The courses of 19 patients with Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome (AIDS) were reviewed. Compared with previous reviews of Pneumocystis pneumonia in patients without AIDS, Pneumocystis pneumonia in patients with AIDS often has a more prolonged clinical prodrome, with pulmonary symptoms occurring for an average of 3 wk prior to presentation, and often has a slower response to therapy, with radiographic and blood gas improvement occurring an average of 13 and 6 days, respectively, after initiation of therapy. No patient diagnosed during life died as a result of Pneumocystis infection; however, 5 required repeat courses of therapy, and 7 required repeat lung biopsies during the course of treatment. Serious side effects of trimethoprim-sulfamethoxazole therapy included fever, rash, and leukopenia, and occurred in 12 patients. Aggressive diagnostic and therapeutic measures combined with prolonged therapy are required for a satisfactory outcome in patients with AIDS and Pneumocystis pneumonia.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free